Research Article
Integron-Mediated Antibiotic Resistance in Acinetobacter baumannii Isolated from Intensive Care Unit Patients, Babol, North of Iran
Table 4
The correlation of class I, II, and III integrons and antibiotic resistance profile.
| | Antibiotics | Positive for integron class I (; 9) | Negative for integron class I (; 26) | value | OR (95 CI) | Positive for integron class II (; 31) | Negative for integron class II (; 4) 8 | value | OR (95 CI) | Positive for integron class III (; 10) | Negative for integron class III (; 25) | value | OR (95 CI) |
| | AN | | | | | | | | | | | | | | R | 9 (25.7%) | 23 (65.7) | 0.287 | 1.666 (0.138–90.16) | 30 (85.7) | 2 (5.7) | 0.002 | 30 (0.915–182) | 10 (28.6) | 22 (62.9) | 0.252 | 1.913 (0.159–102) | | I | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | S | 0 (0) | 3 (8.6) | 1 (2.9) | 2 (5.7) | 0 (0) | 3 (8.6) |
| | GM | | | | | | | | | | | | | | R | 7 (20) | 23 (65.7) | 0.430 | 2.190 (0.303–15.851) | 28 (80) | 2 (5.7) | 0.030 | 9.33 (0.457–159.29) | 10 (28.6) | 20 (57.2) | 0.127 | 3.142 (0.307–157.47) | | I | 1 (2.9) | 0 (0) | 1 (2.9) | 0 (0) | 0 (0) | 1 (2.9) | | S | 1 (2.9) | 3 (8.6) | 2 (5.7) | 2 (5.7) | 0 (0) | 4 (11.4) |
| | CP | | | | | | | | | | | | | | R | 8 (22.6) | 25 (71.4) | 0.418 | 3.125 (0.175–55.886) | 31 (88.6) | 4 (11.4) | 0.000 | 31 (1.576–1675.56) | 9 (25.7) | 24 (68.6) | 0.357 | 1.375 (0.963–78.648) | | I | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | S | 1 (2.9) | 1 (2.9) | 0 (0) | 0 (0) | 1 (2.9) | 1 (2.9) |
| | CAZ | | | | | | | | | | | | | | R | 9 (25.7) | 26 (74.3) | 0.004 | — | 31 (88.6) | 4 (11.4) | 0.000 | — | 10 (28.6) | 25 (71.4) | 0.011 | — | | I | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | S | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | IPM | | | | | | | | | | | | | | R | 8 (22.9) | 25 (71.4) | 0.418 | 3.125 (0.175–55.886) | 31 (88.6) | 2 (5.7) | 0.000 | 32 (2.484–15570.62) | 9 (25.7) | 24 (68.5) | 0.490 | 2.6667 (0.150–47.302) | | I | 1 (2.9) | 1 (2.9) | 0 (0) | 2 (5.7) | 1 (2.9) | 1 (2.9) | | S | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | MER | | | | | | | | | | | | | | R | 9 (25.7) | 24 (68.6) | 0.392 | 1.2 (0.836–69.206) | 31 (88.6) | 2 (5.7) | 0.000 | 32 (2.484–15570.62) | 10 (28.6) | 23 (65.7) | 0.357 | 1.375 (0.963–78.648) | | I | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) | | S | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) | 0 (0) | 1 (2.9) |
| | PIP-TZ | | | | | | | | | | | | | | R | 8 (22.9) | 24 (68.6) | 0.757 | 1.50 (0.119–18.836) | 31 (88.6) | 1 (2.9) | 0.000 | 32 (2.484–15570.62) | 9 (25.7) | 23 (65.7) | 0.849 | 1.278 (0.103–15.899) | | I | 0 (0) | 1 (2.9) | 0 (0) | 2 (5.7) | 0 (0) | 1 (2.9) | | S | 1 (2.9) | 1 (2.9) | 0 (0) | 0 (0) | 1 (2.9) | 1 (2.9) |
|
|
AN: amikacin, GM: gentamicin, CP: ciprofloxacin, CAZ: ceftazidime, IPM: imipenem, MER: meropenem, PIP-TZ: piperacillin-tazobactam, R: resistance, I: intermediate, S: sensitive, and OR: odds ratio.
|
